Document Detail


Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.
MedLine Citation:
PMID:  22431677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effects may differ in persons with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleeding hazards may be increased in this population.
PURPOSE: To summarize the effects of antiplatelet treatment on cardiovascular events, mortality, and bleeding in persons with CKD.
DATA SOURCES: Embase and Cochrane databases through November 2011 without language restriction.
STUDY SELECTION: Randomized trials that included adults with CKD and compared antiplatelet agents with standard care, placebo, or no treatment.
DATA EXTRACTION: Data for populations, interventions, outcomes, and risk for bias were extracted. Quality of evidence for treatment effects on myocardial infarction, death, and bleeding was summarized by using Grading of Recommendations Assessment, Development, and Evaluation guidelines.
DATA SYNTHESIS: Nine trials (all post hoc subgroup analyses for CKD) involving 9969 persons who had acute coronary syndromes or were undergoing percutaneous coronary intervention and 31 trials involving 11,701 persons with stable or no cardiovascular disease were identified. Low-quality evidence has found that in persons with acute coronary syndromes, glycoprotein IIb/IIIa inhibitors or clopidogrel plus standard care compared with standard care alone had little or no effect on all-cause or cardiovascular mortality or on myocardial infarction but increased serious bleeding. Compared with placebo or no treatment in persons with stable or no cardiovascular disease, antiplatelet agents prevented myocardial infarction but had uncertain effects on mortality and increased minor bleeding according to generally low-quality evidence.
LIMITATIONS: Data for antiplatelet agents in persons with CKD are frequently derived from post hoc analyses of trials of broader populations. Definitions for bleeding outcomes and trial duration were heterogeneous.
CONCLUSION: Benefits for antiplatelet therapy among persons with CKD are uncertain and are potentially outweighed by bleeding hazards.
PRIMARY FUNDING SOURCE: None.
Authors:
Suetonia C Palmer; Lucia Di Micco; Mona Razavian; Jonathan C Craig; Vlado Perkovic; Fabio Pellegrini; Massimiliano Copetti; Giusi Graziano; Gianni Tognoni; Meg Jardine; Angela Webster; Antonio Nicolucci; Sophia Zoungas; Giovanni F M Strippoli
Related Documents :
22805997 - Normal values of left and right ventricular function measured by m-mode, pulsed doppler...
21964157 - Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect o...
10499727 - Familial ventricular arrhythmias in boxers.
22764157 - Inducible myocardial ischaemia and anomalous origin of the right coronary artery coursi...
16008157 - Restenosis treatment in the drug-eluting stent era.
12625617 - Biventricular implantable cardioverter defibrillator and inappropriate shocks.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Annals of internal medicine     Volume:  156     ISSN:  1539-3704     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-20     Completed Date:  2012-05-02     Revised Date:  2013-06-25    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  445-59     Citation Subset:  AIM; IM    
Affiliation:
University of Otago, Christchurch, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / mortality,  prevention & control
Bias (Epidemiology)
Cardiovascular Diseases / mortality*,  prevention & control*
Cause of Death
Hemorrhage / chemically induced*
Humans
Myocardial Infarction / mortality,  prevention & control
Myocardial Revascularization
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Renal Insufficiency, Chronic / complications*
Stroke / mortality,  prevention & control
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors
Comments/Corrections
Comment In:
Am J Kidney Dis. 2013 Jan;61(1):18-21   [PMID:  22950975 ]
Ann Intern Med. 2012 Aug 21;157(4):302-3; author reply 303-4   [PMID:  22910952 ]
Ann Intern Med. 2012 Aug 21;157(4):JC2-8   [PMID:  22910962 ]
Ann Intern Med. 2012 Aug 21;157(4):302; author reply 303-4   [PMID:  22910951 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.
Next Document:  A case-control study examining whether neurological deficits and PTSD in combat veterans are related...